| [1] |
Hu C, Yang S, Li S, et al. Viral aptamer screening and aptamer-based biosensors for virus detection: A review[J]. Int J Biol Macromol,2024,276(Pt 2):133935.
|
| [2] |
Kamalrathne T, Amaratunga D, Haigh R, et al. Epidemic and pandemic preparedness and response in a multi-hazard context: COVID-19 pandemic as a point of reference[J]. Int J Environ Res Public Health,2024,21(9):1238.
|
| [3] |
Malarvannan M, Sabavath BTN, Gaddam V, et al. Transformative potentials, challenges and innovative solutions of lipidomics in multiple clinical applications[J]. Talanta,2025,291:127855.
|
| [4] |
Liang Y. Pathogenicity and virulence of influenza[J]. Virulence,2023,14(1):2223057.
|
| [5] |
陈媛, 邓慧玲, 李亚萍, 等. 357例流行性感冒患儿血清25-羟基维生素D水平及其与重症化的关联性[J/OL]. 中华实验和临床感染病杂志(电子版),2022,16(6):410-417.
|
| [6] |
Zheng Y, Zhang Y, Chen Y, et al. Indoleamine 2, 3-dioxygenase 1 drives epithelial cells ferroptosis in influenza-induced acute lung injury[J]. Redox Biol,2025,81:103572.
|
| [7] |
Chen W, Gu Y, Ma Y, et al. Profiling lipid mediators in serum from children with H1N1 influenza[J]. Sci Rep,2024,14(1):15186.
|
| [8] |
Zhou Y, Pu J, Wu Y. The role of lipid metabolism in influenza a virus infection[J]. Pathogens,2021,10(3):303.
|
| [9] |
Zhang C, Li W, Lei X, et al. Targeting lysophospholipid acid receptor 1 and ROCK kinases promotes antiviral innate immunity[J]. Sci Adv,2021,7(38):eabb5933.
|
| [10] |
Zhang H, Hu F, Peng O, et al. Multi-omics analysis by machine learning identified lysophosphatidic acid as a biomarker and therapeutic target for porcine reproductive and respiratory syndrome[J]. Adv Sci (Weinh),2024,11(34):e2402025.
|
| [11] |
Gowda D, Ohno M, B Gowda SG, et al. Defining the kinetic effects of infection with influenza virus A/PR8/34 (H1N1) on sphingosine-1-phosphate signaling in mice by targeted LC/MS[J]. Sci Rep,2021,11(1):20161.
|
| [12] |
Teijaro JR, Walsh KB, Long JP, et al. Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapy[J]. Virology,2014,452-453:152-157.
|
| [13] |
Zhang Z, Karu N, Kindt A, et al. Association of altered plasma lipidome with disease severity in COVID-19 patients[J]. Biomolecules,2024,14(3):296.
|
| [14] |
Wei C, Wan L, Yan Q, et al. HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry[J]. Nat Metab,2020,2(12):1391-1400.
|
| [15] |
Ramirez S, Fernandez-Antunez C, Galli A, et al. Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication[J]. Antimicrob Agents Chemother,2021,65(7):e0009721.
|
| [16] |
Song JW, Lam SM, Fan X, et al. Omics-driven systems interrogation of metabolic mysregulation in COVID-19 pathogenesis[J]. Cell Metab,2020,32(2):188-202. e5.
|
| [17] |
Saballs M, Parra S, Martínez N, et al. Lipidomic and metabolomic changes in community-acquired and COVID-19 pneumonia[J]. J Lipid Res,2024,65(9):100622.
|
| [18] |
Theken KN, Tang SY, Sengupta S, et al. The roles of lipids in SARS-CoV-2 viral replication and the host immune response[J]. J Lipid Res,2021,62:100129.
|
| [19] |
Schwarz B, Sharma L, Roberts L, et al. Cutting edge: severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome, resulting in dysregulation of eicosanoid immune mediators[J]. J Immunol,2021,206(2):329-334.
|
| [20] |
Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19[J]. Nat Med,2020,26(6):842-844.
|
| [21] |
Sahanic S, Löffler-Ragg J, Tymoszuk P, et al. The role of innate immunity and bioactive lipid mediators in COVID-19 and influenza[J]. Front Physiol,2021,12:688946.
|
| [22] |
Dos SP Andrade AC, Lacasse E, Dubuc I, et al. Deficiency in platelet 12-lipoxygenase exacerbates inflammation and disease severity during SARS-CoV-2 infection[J]. Proc Natl Acad Sci USA,2025,122(12):e2420441122.
|
| [23] |
Tasat DR, Yakisich JS. Rationale for the use of sphingosine analogues in COVID-19 patients[J]. Clin Med (Lond),2021,21(1):e84-e87.
|
| [24] |
Teymouri S, Pourbayram Kaleybar S, Hejazian SS, et al. The effect of fingolimod on patients with moderate to severe COVID-19[J]. Pharmacol Res Perspect,2023,11(1):e01039.
|
| [25] |
国家感染性疾病医疗质量控制中心. 人类免疫缺陷病毒感染诊治质量改进专家共识[J/OL]. 中华实验和临床感染病杂志(电子版),2025,19(1):1-8.
|
| [26] |
Tran N, Oh Y, Sutherland M, et al. Cholesterol-mediated clustering of the HIV fusion protein gp41 in lipid bilayers[J]. J Mol Biol,2022,434(2):167345.
|
| [27] |
Mikaeloff F, Gelpi M, Benfeitas R, et al. Network-based multi-omics integration reveals metabolic at-risk profile within treated HIV-infection[J]. Elife,2023,12:e82785.
|
| [28] |
Lin KH, Vilar-Gomez E, Corey KE, et al. MASLD in persons with HIV is associated with high cardiometabolic risk as evidenced by altered advanced lipoprotein profiles and targeted metabolomics[J]. Lipids Health Dis,2024,23(1):339.
|
| [29] |
So-Armah K, Benjamin LA, Bloomfield GS, et al. HIV and cardiovascular disease[J]. Lancet HIV,2020,7(4):e279-e293.
|
| [30] |
Wan Z, Su J, Zhu X, et al. Distinct lipidomic profiles between people living with HIV treated with E/C/F/TAF or B/F/TAF: an open-label prospective cohort study[J]. Infect Dis Ther,2024,13(4):727-744.
|
| [31] |
Vos W, Vadaq N, Matzaraki V, et al. Cardiometabolic differences in people living with HIV receiving integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors: implications for current ART strategies[J]. Viruses,2024,16(4):582.
|
| [32] |
Yuan NY, Maung R, Xu Z, et al. Arachidonic acid cascade and eicosanoid production are elevated while LTC4 synthase modulates the lipidomics profile in the brain of the HIVgp120-transgenic mouse model of neuroHIV[J]. Cells,2022,11(13):2123.
|
| [33] |
Zhang E, Chai JC, Deik AA, et al. Plasma lipidomic profiles and risk of diabetes: 2 prospective cohorts of HIV-infected and HIV-uninfected individuals[J]. J Clin Endocrinol Metab,2021,106(4):999-1010.
|
| [34] |
Tordrup D, Hutin Y, Stenberg K, et al. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30[J]. Lancet Glob Health,2019,7(9):e1180-e1188.
|
| [35] |
Yu L, Zeng Z, Tan H, et al. Significant metabolic alterations in patients with hepatitis B virus replication observed via serum untargeted metabolomics shed new light on hepatitis B virus infection[J]. J Drug Target,2022,30(4):442-449.
|
| [36] |
Li H, Xu Q Y, Xie Y, et al. Effects of chronic HBV infection on lipid metabolism in non-alcoholic fatty liver disease: A lipidomic analysis[J]. Ann Hepatol,2021,24:100316.
|
| [37] |
Zhu Y, Zhao Y, Ning Z, et al. Metabolic self-feeding in HBV-associated hepatocarcinoma centered on feedback between circulation lipids and the cellular MAPK/mTOR axis[J]. Cell Commun Signal,2024,22(1):280.
|
| [38] |
Reichert I, Lee JY, Weber L, et al. The triglyceride-synthesizing enzyme diacylglycerol acyltransferase 2 modulates the formation of the hepatitis C virus replication organelle[J]. PLoS Pathog,2024,20(9):e1012509.
|
| [39] |
Ito M, Liu J, Fukasawa M, et al. Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation[J]. JHEP Rep,2025,7(1):101225.
|
| [40] |
Abomughaid M, Tay ESE, Pickford R, et al. PEMT mediates hepatitis C virus-induced steatosis, explains genotype-specific phenotypes and supports virus replication[J]. Int J Mol Sci,2023,24(10):8781.
|
| [41] |
Islam KU, Anwar S, Patel AA, et al. Global lipidome profiling revealed multifaceted role of lipid species in hepatitis C virus replication, assembly, and host antiviral response[J]. Viruses,2023,15(2):464.
|
| [42] |
Beyoğlu D, Schwalm S, Semmo N, et al. Hepatitis C virus infection upregulates plasma phosphosphingolipids and endocannabinoids and downregulates lysophosphoinositols[J]. Int J Mol Sci,2023,24(2):1407.
|
| [43] |
Yan B, Zou Z, Chu H, et al. Lipidomic profiling reveals significant perturbations of intracellular lipid homeostasis in enterovirus-infected cells[J]. Int J Mol Sci,2019,20(23):5952.
|
| [44] |
Kline I, Mokry RL, Xi Y, et al. Human cytomegalovirus promotes de novo PC synthesis during early virus replication[J]. bioRxiv,2025,99(9):e0057925.
|
| [45] |
Yang B, Shi C, Tang Y, et al. Integrated untargeted and targeted lipidomics discovers LPE 16:0 as a protector against respiratory syncytial virus infection[J]. J Pharm Biomed Anal,2024,250:116399.
|
| [46] |
Yousefi M, Lee WS, Yan B, et al. TMEM41B and VMP1 modulate cellular lipid and energy metabolism for facilitating dengue virus infection[J]. PLoS Pathog,2022,18(8):e1010763.
|
| [47] |
Queiroz A, Pinto IFD, Lima M, et al. Lipidomic analysis reveals serum alteration of plasmalogens in patients infected with ZIKA virus[J]. Front Microbiol,2019,10:753.
|
| [48] |
Leier HC, Weinstein JB, Kyle JE, et al. A global lipid map defines a network essential for Zika virus replication[J]. Nat Commun,2020,11(1):3652.
|